Sunday, October 24, 2010

India to screen over 7 crore adults above 30 years of age for diabetes, blood pressure-July 8, 2010,

India to screen over 7 crore adults above 30 years of age for diabetes, blood pressure


Thursday, July 8, 2010, 20:42 This news item was posted in health category and has 0 Comments so far.
Indian health authorities are expected to screen over seven crore adult population in the age group of 30 years & above for diabetes and hypertension, as a measure to prevent the diseases through early diagnosis and treatment at early stages.


Early screening and prevention of Non Communicable Disease (NCD) including diabetes and stroke is part of the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS).

The Centre has already earmarked an outlay of Rs 1230.90 crore for the programme.

The health authorities aim opportunistic and targeted screening, diagnosis and management of NCDs.

Through successfully implementing the programme, the health authorities expect to achieve behaviour change in the community to adopt healthy life styles including dietary patterns, enhanced physical activity and reduced intake of tobacco and alcohol resulting in overall reduction in the risk factors of common NCDs in the community.

The programme will be implemented in 20,000 sub-centres and 700 community health centres (CHCs) in 100 districts across 15 states/UTs by promoting healthy lifestyle through massive health education and mass media efforts at country level, opportunistic screening of persons above the age of 30 years, establishment of Non Communicable Disease (NCD) clinics at CHC and district level, development of trained manpower and strengthening of tertiary level health facilities.

To fill the gap in the health delivery system, about 32,000 health personnel would be trained at various levels to provide opportunistic and targeted screening, diagnosis and management of NCDs.

The Cabinet Committee on Economic Affairs has given the approval for the NPCDCS for implementation of its various components during the remaining period of 11th Five year plan ( 2010-11 & 2011-12) at an estimated outlay of Rs 1230.90 crore (Rs 499.38 crore for interventions on diabetes and cardiovascular diseases & stroke and Rs 731.52 crore for cancer control) on a cost sharing basis between the Centre and the states at the rate of 80:20.

It also approved the inter-usability of funds from one component to another within the same group of diseases, limited to a ceiling of 10 per cent, in order to impart operational flexibility in implementation of these programs.

Transfer of funds from one component to the other beyond this limit would be decided by the Empowered Programme Committee (EPC) and Mission Steering Group (MSG).

Approval has also been accorded for empowering the MSG and EPC setup under the National Rural Health Mission (NRHM) to approve financial norms in respect of all components of the Programme.

A recent study conducted by Aventis Pharma Ltd found that 21% of Delhiites suffer from both diabetes and hypertension leading to a possible twin epidemic.

Of the diabetic population in New Delhi already aware of their condition, almost two-of-every-three (62%) had ‘uncontrolled’ diabetes with their Hba1c levels more than 7% and of the hypertensive population three-out-of-four were uncontrolled.

Almost half the population tested in the New Delhi region has uncontrolled levels of lipids (dyslipidemia) as compared to about one-fifth of the Maharashtra population.
Cardiovascular death rates are high and appear to be climbing in countries like India where diabetes is highly prevalent.

In India, in the past five decades, rates of coronary disease among urban population have risen from 4% to 11%.

The World Health Organisation (WHO) estimates that 60% of the world’s cardiac patients will be Indians by 2010. With the rising tide of diabetes in India, the double jeopardy of diabetes and hypertension is set to result in an explosion of cardiovascular and other complications – unless preventive action is taken now, alerts the Sanofi study.

No comments: